The US Food and Drug Administration has approved a new medication for Type 2 diabetes called Brenzavvy. This belongs to a class of drugs known as SGLT-2 inhibitors, which work by helping the body remove excess glucose (sugar) through the urine.
Brenzavvy was approved based on results from 23 clinical trials, which showed that the medication effectively lowered blood sugar levels and improved overall diabetes control. The most common side effect of Brenzavvy was yeast infections.
Brenzavvy, which can be used alone or in combination with other diabetes medications, is not approved for people with Type 1 diabetes.
Brenzavvy is now the fifth SGLT-2 inhibitor approved in the US, along with Invokana (canagliflozin), Farxiga (dapagliflozin), Jardiance (empagliflozin), and Steglatro (ertugliflozin).
To read more CLICK HERE.
